<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7779056</article-id>
    <article-id pub-id-type="pmid">33045737</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkaa755</article-id>
    <article-id pub-id-type="publisher-id">gkaa755</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>INTEDE: interactome of drug-metabolizing enzymes</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Yin</surname>
          <given-names>Jiayi</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <xref ref-type="author-notes" rid="FN1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Fengcheng</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <xref ref-type="author-notes" rid="FN1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhou</surname>
          <given-names>Ying</given-names>
        </name>
        <aff><institution>The First Affiliated Hospital, Zhejiang University</institution>, Hangzhou 310000, <country country="CN">China</country></aff>
        <xref ref-type="author-notes" rid="FN1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mou</surname>
          <given-names>Minjie</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <xref ref-type="author-notes" rid="FN1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lu</surname>
          <given-names>Yinjing</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Kangli</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xue</surname>
          <given-names>Jia</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Luo</surname>
          <given-names>Yongchao</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Fu</surname>
          <given-names>Jianbo</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>He</surname>
          <given-names>Xu</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gao</surname>
          <given-names>Jianqing</given-names>
        </name>
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <aff><institution>Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University</institution>, Hangzhou 310018, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zeng</surname>
          <given-names>Su</given-names>
        </name>
        <!--<email>zengsu@zju.edu.cn</email>-->
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <aff><institution>Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University</institution>, Hangzhou 310018, <country country="CN">China</country></aff>
        <xref ref-type="corresp" rid="COR2"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yu</surname>
          <given-names>Lushan</given-names>
        </name>
        <!--<email>yuls@zju.edu.cn</email>-->
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <xref ref-type="corresp" rid="COR3"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8069-0053</contrib-id>
        <name>
          <surname>Zhu</surname>
          <given-names>Feng</given-names>
        </name>
        <!--<email>zhufeng@zju.edu.cn</email>-->
        <aff><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou 310058, <country country="CN">China</country></aff>
        <aff><institution>Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University</institution>, Hangzhou 310018, <country country="CN">China</country></aff>
        <xref ref-type="corresp" rid="COR1"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 189 8946 6518; Fax: +86 571 8820 8444; Email: <email>zhufeng@zju.edu.cn</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Prof. Su Zeng. Email: <email>zengsu@zju.edu.cn</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Prof. Lushan Yu. Email: <email>yuls@zju.edu.cn</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first four authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>08</day>
      <month>1</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2020-10-12">
      <day>12</day>
      <month>10</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>12</day>
      <month>10</month>
      <year>2020</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
    <volume>49</volume>
    <issue>D1</issue>
    <fpage>D1233</fpage>
    <lpage>D1243</lpage>
    <history>
      <date date-type="accepted">
        <day>22</day>
        <month>9</month>
        <year>2020</year>
      </date>
      <date date-type="rev-recd">
        <day>19</day>
        <month>8</month>
        <year>2020</year>
      </date>
      <date date-type="received">
        <day>20</day>
        <month>7</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkaa755.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Drug-metabolizing enzymes (DMEs) are critical determinant of drug safety and efficacy, and the interactome of DMEs has attracted extensive attention. There are 3 major interaction types in an interactome: microbiome–DME interaction (MICBIO), xenobiotics–DME interaction (XEOTIC) and host protein–DME interaction (HOSPPI). The interaction data of each type are essential for drug metabolism, and the collective consideration of multiple types has implication for the future practice of precision medicine. However, no database was designed to systematically provide the data of all types of DME interactions. Here, a database of the Interactome of Drug-Metabolizing Enzymes (INTEDE) was therefore constructed to offer these interaction data. First, 1047 unique DMEs (448 host and 599 microbial) were confirmed, for the first time, using their metabolizing drugs. Second, for these newly confirmed DMEs, all types of their interactions (3359 MICBIOs between 225 microbial species and 185 DMEs; 47 778 XEOTICs between 4150 xenobiotics and 501 DMEs; 7849 HOSPPIs between 565 human proteins and 566 DMEs) were comprehensively collected and then provided, which enabled the crosstalk analysis among multiple types. Because of the huge amount of accumulated data, the INTEDE made it possible to generalize key features for revealing disease etiology and optimizing clinical treatment. INTEDE is freely accessible at: <ext-link ext-link-type="uri" xlink:href="https://idrblab.org/intede/">https://idrblab.org/intede/</ext-link></p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig id="ga1" orientation="portrait" position="float">
          <label>Graphical Abstract</label>
          <caption>
            <p>The Interactome Database of Drug-Metabolizing Enzyme (INTEDE) provides the comprehensive interactome data from three perspectives for both human and microbial drug-metabolizing enzymes.</p>
          </caption>
          <graphic xlink:href="gkaa755gra1"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Key Research and Development Program of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100012166</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2017YFC0908600</award-id>
        <award-id>2018YFC0910500</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>U1909208</award-id>
        <award-id>81872798</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Key R&amp;D Program of Zhejiang Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2020C03010</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Central Universities</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2018QNA7023</award-id>
        <award-id>10611CDJXZ238826</award-id>
        <award-id>2018CDQYSG0007</award-id>
        <award-id>CDJZR14468801</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Zhejiang University</institution>
            <institution-id institution-id-type="DOI">10.13039/501100004835</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>China Knowledge Centre for Engineering Sciences and Technology</institution>
            <institution-id institution-id-type="DOI">10.13039/501100012455</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>CKCEST-2019-1-12</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="11"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Drug-metabolizing enzymes (DMEs) transform the parent drug to a metabolite with substantially different physicochemical and pharmacological properties, and are critical determinants of drug safety and efficacy (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). The interactome of DMEs has therefore attracted considerable attention (<xref rid="B3" ref-type="bibr">3–12</xref>). There are three major types of interactions: (i) microbiome–DME interactions (MICBIOs) determining the dynamic nature (<xref rid="B5" ref-type="bibr">5</xref>) and interpersonal variability (<xref rid="B6" ref-type="bibr">6</xref>) of drug metabolism; (ii) host protein–DME interactions (HOSPPIs) essential for predicting <italic>in vivo</italic> efficacy or clearance based on <italic>in vitro</italic> result (<xref rid="B7" ref-type="bibr">7</xref>) and revealing the mechanism underlying drug resistance (<xref rid="B8" ref-type="bibr">8</xref>) or adverse drug reaction (<xref rid="B9" ref-type="bibr">9</xref>); (iii) xenobiotics–DME interactions (XEOTICs) that are the key factor of metabolism-based drug–drug interaction (<xref rid="B5" ref-type="bibr">5</xref>) and a constant inspiration of clinical treatment optimization (<xref rid="B10" ref-type="bibr">10</xref>). Because the metabolism of drugs is collectively determined by multiple types of interactions, the accumulation of DME interactome data may give vital insight into the prediction of clinical consequences (<xref rid="B7" ref-type="bibr">7</xref>) and will have implication for the future practice of precision medicine (<xref rid="B5" ref-type="bibr">5</xref>).</p>
    <p>Moreover, because of its dynamic evolvements (<xref rid="B5" ref-type="bibr">5</xref>), wide distribution (<xref rid="B13" ref-type="bibr">13</xref>), and rich repository of enzymes (<xref rid="B14" ref-type="bibr">14</xref>), the microbiome and its DMEs are found to be not only as critical as human DMEs in drug metabolism (<xref rid="B10" ref-type="bibr">10</xref>), but also key in the study of individual or tissue-specific metabolism of drugs (<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>) and the discovery of novel therapeutics targeting microbial protein (<xref rid="B10" ref-type="bibr">10</xref>). As a result, there was an explosive growth of interest in studying the interactome of microbial DME (<xref rid="B15" ref-type="bibr">15–19</xref>). Particularly, the MICBIO between actinobacteria <italic>Eggerthella lenta</italic> and microbial DME tyrosine decarboxylases was found to collectively regulate the metabolism of levodopa (<xref rid="B10" ref-type="bibr">10</xref>); the HOSPPI between host UDP-glucuronosyltransferases and microbial DME beta-glucuronidases could lead to an adverse drug reaction of irinotecan (<xref rid="B20" ref-type="bibr">20</xref>); the XEOTIC between antibiotic ciprofloxacin and bacterial DME cytidine deaminase was discovered to abrogate the resistance of gemcitabine (<xref rid="B21" ref-type="bibr">21</xref>). Thus, it is important to collect these interactome data, and collectively analyze the multiple types of interactions for not only human but also microbial DMEs (<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B15" ref-type="bibr">15</xref>).</p>
    <p>Nowadays, various databases have been developed to provide DME-related data, the majority of which are freely accessible and remain active. Some of these databases (such as DrugBank (<xref rid="B22" ref-type="bibr">22</xref>), PDB (<xref rid="B23" ref-type="bibr">23</xref>), PharmGKB (<xref rid="B24" ref-type="bibr">24</xref>), Protein Atlas (<xref rid="B25" ref-type="bibr">25</xref>), TTD (<xref rid="B26" ref-type="bibr">26</xref>) and UniProt (<xref rid="B27" ref-type="bibr">27</xref>)) provide the enzyme or DME information as part of a broader collection of biological/pharmacological data, and some others (including BRENDA (<xref rid="B28" ref-type="bibr">28</xref>), KEGG (<xref rid="B29" ref-type="bibr">29</xref>), MetaCyc (<xref rid="B30" ref-type="bibr">30</xref>), Reactome (<xref rid="B31" ref-type="bibr">31</xref>), SMPDB (<xref rid="B32" ref-type="bibr">32</xref>) and VMH (<xref rid="B33" ref-type="bibr">33</xref>)) contain the general enzymatic classifications or metabolic reaction/pathway data for a comprehensive set of enzymes. Since all these databases do not include DME interactome data, some databases have been designed to provide the interactions between ∼2800 xenobiotics and ∼190 DMEs (including CTD (<xref rid="B34" ref-type="bibr">34</xref>), T3DB (<xref rid="B35" ref-type="bibr">35</xref>) and Transformer (<xref rid="B36" ref-type="bibr">36</xref>)). However, no database has been designed to describe the key role of microbial DME in drug metabolism, and the interaction data of neither microbiome (MICBIO) nor host protein (HOSPPI), that alter drug metabolism by affecting human/microbial DME, are provided in any available knowledge base. As the crosstalk among interaction types is crucial for drug metabolism (<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B15" ref-type="bibr">15</xref>), it is critical to construct a database that comprehensively describes all three types of DME interactions.</p>
    <p>Here, a newly developed database, Interactome of Drug-Metabolizing Enzyme (INTEDE) was therefore introduced. First, a comprehensive literature review of all (&gt;1900) drugs approved by U.S. FDA and &gt;3000 drugs in clinical trial or preclinical research was performed. Different from the small amount of DMEs (∼30) that were officially described in the U.S. FDA guidance (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>), 553 DMEs (241 and 312 from human and microbiome, respectively) were confirmed in INTEDE to metabolize approved drugs, 421 DMEs (188 from human and 233 from microbiome) were to metabolize the drug in clinical or preclinical test, and 494 DMEs (208 from human and 286 from microbiome) were to metabolize the pharmaceutically investigative agents. Second, for all these newly confirmed DMEs, INTEDE comprehensively provided all three types of their interactions (MICBIOs, HOSPPIs and XEOTICs, as shown in Figure <xref ref-type="fig" rid="F1">1</xref>), which allowed the crosstalk among multiple interaction types (<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B15" ref-type="bibr">15</xref>) and could thus facilitate the study of disease etiology and the optimization of clinical treatment. All in all, since such crosstalk is key for drug metabolism, the INTEDE is expected to have implications for the future practice of precision medicine.</p>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1.</label>
      <caption>
        <p>INTEDE statistics of (i) the DMEs, and their corresponding drug(s) and tissue/disease specific protein abundances (<italic>orange</italic>) and (ii) three types of DME interactions: MICBIOs (<italic>green</italic>), HOSPPIs (<italic>blue</italic>) and XEOTICs (<italic>red</italic>). MICBIO determines the evolving and dynamic nature of metabolizing capacity and the interpersonal variability of drug metabolism; HOSPPI is essential for predicting <italic>in vivo</italic> efficacy/clearance based on the <italic>in vitro</italic> data, and revealing the mechanisms underlying drug resistance and toxicity; XEOTIC is one of the leading factors of the metabolism-based drug-drug interaction and the constant inspiration of clinical treatment optimization.</p>
      </caption>
      <graphic xlink:href="gkaa755fig1"/>
    </fig>
  </sec>
  <sec id="SEC2">
    <title>FACTUAL CONTENT AND DATA RETRIEVAL</title>
    <sec id="SEC2-1">
      <title>Confirmation and collection of human/microbial DMEs</title>
      <p>The DMEs collected in INTEDE were first confirmed by the drugs of clinical importance (either approved or clinical/preclinical/investigative). Particularly, a comprehensive literature review of all drugs approved by FDA (1921 in total, collected from the U.S. FDA official site), 2958 drugs in clinical trial (data from the <italic>ClinicalTrial.gov</italic> (<xref rid="B39" ref-type="bibr">39</xref>) and TTD (<xref rid="B40" ref-type="bibr">40</xref>)) and 10 213 pharmaceutically investigative agents (obtained from the TTD (<xref rid="B40" ref-type="bibr">40</xref>)), was performed to confirm their corresponding DMEs by searching the PubMed (<xref rid="B41" ref-type="bibr">41</xref>) using such keyword combinations as ‘‘Drug Name’ + drug metabolizing enzyme’, ‘‘Drug Name’ + metabolism’, ‘‘Drug Name’ + enzyme’, ‘‘Drug Name’ + drug metabolism’ and ‘‘Drug Name’ + metabolized’. Moreover, to facilitate the discovery of microbial DMEs, &gt;2000 microbial species (from bacteria, fungi, metamonada, amoebozoa and archaea (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B42" ref-type="bibr">42</xref>,<xref rid="B43" ref-type="bibr">43</xref>)) colonizing throughout the human body (such as bladder, blood, eye, gut, lung, oral cavity, skin, stomach, urethra and vagina (<xref rid="B44" ref-type="bibr">44–46</xref>)) were collected, and the microbial DMEs were then discovered by the literature review of PubMed (<xref rid="B41" ref-type="bibr">41</xref>) using such keyword combinations as ‘‘Species Name’ + ‘Drug Name’’, ‘‘Species Name’ + drug metabolism’, ‘‘Species Name’ + drug metabolized’ and ‘‘Species Name’ + metabolizing enzyme’.</p>
      <p>As a result, 553 DMEs (241 host and 312 microbial) were identified to metabolize 924 approved drugs, 421 DMEs (188 host and 233 microbial) were to metabolize 560 drugs in preclinical and clinical, and 494 DMEs (208 host and 286 microbial) were to metabolize 405 pharmaceutically investigative agents. In total, there were 1047 unique DMEs in INTEDE (448 from human and 599 from microbes). On one hand, 448 human DMEs were grouped to diverse enzymatic families (43 families in total defined by the second level of the Enzyme Commission (EC) nomenclature (<xref rid="B28" ref-type="bibr">28</xref>)), and the Top-5 popular DME families were: <italic>Paired Donor Oxidoreductase</italic> (EC: 1.14, 67 DMEs), <italic>CH-OH Donor Oxidoreductase</italic> (EC: 1.1, 47 DMEs), <italic>Ester Bond Hydrolase</italic> (EC: 3.1, 41 DMEs), <italic>Glycosyltransferase</italic> (EC: 2.4, 34 DMEs) and <italic>Kinase</italic> (EC:2.7, 32 DMEs). On the other hand, 599 microbial DMEs also belonged to diverse enzymatic families (29 families in total defined by the second level of EC nomenclature), and the Top-5 popular DME families were: <italic>Carbon-Nitrogen Hydrolase</italic> (EC: 3.5, 99 DMEs), <italic>Glycosylase</italic> (EC: 3.2, 91 DMEs), <italic>Paired Donor Oxidoreductase</italic> (EC: 1.14, 33 DMEs), <italic>CH-NH Donor Oxidoreductase</italic> (EC: 1.5, 31 DMEs), and <italic>Acyltransferase</italic> (EC: 2.3, 20 DMEs). Experimentally assessed kinetic parameters (<italic>Km</italic>) and catalytic efficiencies (<italic>Kcat</italic>/<italic>Km</italic>) between 235 drugs and 190 human/microbial DMEs were also offered. As shown in Figure <xref ref-type="fig" rid="F2">2</xref>, a full list of drugs metabolized by certain DME were displayed in INTEDE.</p>
      <fig id="F2" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>A typical INTEDE page providing the details of DME, which included: (i) the general information (DME name, EC nomenclature, taxonomy lineage, hyperlink to detailed interactome and molecular or functional data); (ii) the full list of drugs metabolized by this DME (categorized based on clinical status: FDA approved, clinical, preclinical, investigative and discontinued. By clicking on each category, the detail information of each drug can be viewed); (iii) the tissue and disease specific protein abundance of the DME (the differential abundance profiles of 394 DMEs in 60 tissues and 106 diseases, and the expression profiles of 348 DMEs across 36 human tissues).</p>
        </caption>
        <graphic xlink:href="gkaa755fig2"/>
      </fig>
    </sec>
    <sec id="SEC2-2">
      <title>Tissue and disease specific protein sbundances of DMEs</title>
      <p>Tissue and disease specific DME abundances are critical for the mitigation of drug toxic reaction (<xref rid="B47" ref-type="bibr">47</xref>) and alteration of drug pharmacokinetics (<xref rid="B48" ref-type="bibr">48</xref>). In particular, tissue specific DME abundances can not only maintain the functional homeostasis of drug, but also mitigate their tissue-dependent adverse reactions, such as cardiotoxicity, nephrotoxicity and neurotoxicity (<xref rid="B47" ref-type="bibr">47</xref>); the variations in DME abundances among different disease indications (such as infection, immunodeficiency and inflammation) can significantly affect hepatic/renal clearance, and therefore reduce drug efficacy or aggravate adverse drug reaction (<xref rid="B48" ref-type="bibr">48</xref>). Since these tissue/disease-dependent variations in DME abundances were expected to provide new therapeutic strategies (<xref rid="B49" ref-type="bibr">49–52</xref>), the relevant data should be accumulated and further analyzed to promote modern drug discovery.</p>
      <p>Disease specific DME abundance data were collected as follows, the detailed procedure of which was illustrated in <xref ref-type="supplementary-material" rid="sup1">Supplementary Method S1</xref>. First, 5304 series records from the same microarray platform (Affymetrix HGU133 Plus 2.0) were gathered from the Gene Expression Omnibus (<xref rid="B53" ref-type="bibr">53</xref>). Second, the collected records were sequentially processed by data normalization, transformation, integration, perfect match correction, quantile, robust multiarray average and median polish (<xref rid="B54" ref-type="bibr">54</xref>). Third, the differential expression analysis (<xref rid="B55" ref-type="bibr">55</xref>) was conducted by comparing the DME abundance among sample groups (defined in <xref ref-type="supplementary-material" rid="sup1">Supplementary Method S1</xref>). Fourth, the violin-plot describing the differential expression pattern of the studied DMEs among sample groups was drawn (shown in <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S1</xref>). Furthermore, tissue specific DME abundances data were collected using the following procedure, and the detailed process was elaborated in <xref ref-type="supplementary-material" rid="sup1">Supplementary Method S1</xref>. First, a benchmark dataset that contained the protein expression data across 36 human tissues (<xref rid="B56" ref-type="bibr">56</xref>) was collected. Second, the intensities of each DME were processed via data integration and scaling. Third, the expression bar plot of studied DME across 36 tissues was drawn (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S2</xref>). Overall, the differential abundance profile of 394 DMEs in 20,663 patients and healthy individuals of 60 tissues and 106 diseases, and the expression profile of 348 DMEs across 36 human tissues were provided in and downloadable from the website. As shown in Figure <xref ref-type="fig" rid="F2">2</xref>, the tissue and disease specific DME abundances were described.</p>
    </sec>
    <sec id="SEC2-3">
      <title>The interactome of human and microbial DMEs</title>
      <p>INTEDE comprehensively provided all three types of DME interaction data (as shown in Figure <xref ref-type="fig" rid="F1">1</xref>) for those 1047 unique DMEs (448 from human and 599 from microbe) confirmed in previous section. These interaction data included: (i) microbiome–DME interactions (MICBIOs); (ii) host protein–DME interactions (HOSPPIs) and (iii) xenobiotics–DME interactions (XEOTICs).</p>
      <sec id="SEC2-3-1">
        <title>Interactions between microbiome and DMEs</title>
        <p>The microbial manipulation of drug metabolism by interacting with DME is characterized by (i) the vast diversity of involved microbial species (including various bacteria or fungi from dozens of taxonomic phyla (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B57" ref-type="bibr">57–59</xref>)) and (ii) the wide distribution of these species throughout the human body (not only in gut, but also in skin, vagina, and many other sites (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B60" ref-type="bibr">60–62</xref>)). Since the microbiome-DME interactions (MICBIOs) are key in determining the dynamic feature (<xref rid="B5" ref-type="bibr">5</xref>) and interpersonal variability (<xref rid="B6" ref-type="bibr">6</xref>) of drug metabolism, it is very essential to have the MICBIOs data for understanding the controls/effects of the circadian timing system (<xref rid="B63" ref-type="bibr">63</xref>) and individualized microbiota compositions (<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B61" ref-type="bibr">61</xref>) on the metabolism of certain medication (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
        <p>Because the MICBIOs data were largely dispersed in literatures, PubMed database (<xref rid="B41" ref-type="bibr">41</xref>) was first searched to find the interactions between microbiome and human/microbial DMEs. In particular, the keyword combinations of ‘‘Microbial Species Name’ + ‘DME Name’’, ‘‘Species Name’ + ‘Drug Name’’ and ‘‘Species Name’ + drug metabolism’ were used in literature reviews, and the discovered publications were manually assessed for retrieving any MICBIOs-related information. Moreover, due to the collective determination by multiple factors present in a drug delivery route (<xref rid="B64" ref-type="bibr">64</xref>), the metabolism of a drug should be assessed by simultaneously considering its DME(s) and the colonizing microbes, if both DME and microbe are involved in the same route (<xref rid="B64" ref-type="bibr">64</xref>). Therefore, additional literature reviews were then conducted using the keyword combination of ‘‘Microbial Species Name’ + ‘DME Name’ + ‘Drug Name’’. The studies that describe the DME and microbe that metabolized the same drug and present in the same delivery route were identified, and these publications were also manually evaluated for retrieving the MICBIOs-related data.</p>
        <p>As a result, the collected data included the taxonomic lineage of each microbe (kingdom, phylum, class, order, family, genus and species), the human body site distributed by each microbe (bladder, blood, eye, gut, lung, oral cavity, skin, stomach, urethra and vagina), the list of drugs affected by the interaction between microbial species and DME, and the mechanism of how drug metabolism is influenced by the corresponding interactions. All in all, the latest version of INTEDE contained 3359 MICBIOs between 225 microbes and 185 human/microbial DMEs. These microbes came from 3 kingdoms, 19 phyla, 31 classes, 40 orders, 69 families and 107 genera as defined by the NCBI Taxonomy database (<xref rid="B65" ref-type="bibr">65</xref>), and colonized in 10 different human body sites (such as: bladder, blood, eye, gut, lung, oral cavity, skin, stomach, urethra and vagina). The MICBIOs data can be assessed and retrieved by various search strategies in both the Home page and the subpage entitled ‘Microbiome-DME interaction’ of INTEDE (as shown in Figure <xref ref-type="fig" rid="F3">3</xref>).</p>
        <fig id="F3" orientation="portrait" position="float">
          <label>Figure 3.</label>
          <caption>
            <p>A typical INTEDE page offering the data of microbiome-DME interaction (MICBIO). The INTEDE contained 3359 MICBIOs between 225 microbes and 185 DMEs. These microbes came from 3 kingdoms, 19 phyla, 69 families and 107 genera, and colonized in 10 different host body sites (bladder, blood, eye, gut, lung, oral cavity, skin, stomach, urethra and vagina).</p>
          </caption>
          <graphic xlink:href="gkaa755fig3"/>
        </fig>
      </sec>
      <sec id="SEC2-3-2">
        <title>Interactions between host proteins and DMEs</title>
        <p>Host protein–DME interactions (HOSPPIs) were frequently encountered in drug metabolism, and widely acknowledged to be critical determinant of drug safety and efficacy (<xref rid="B7" ref-type="bibr">7–9</xref>,<xref rid="B66" ref-type="bibr">66–69</xref>). A variety of HOSPPIs were of great interest in recent metabolic study, which included (i) oligomerizations that are essential for predicting <italic>in vivo</italic> drug efficacy or clearance based on the <italic>in vitro</italic> results (<xref rid="B7" ref-type="bibr">7</xref>), (ii) transcription factor regulations that are critical for revealing the mechanisms underlying drug resistance (<xref rid="B8" ref-type="bibr">8</xref>) and metabolic variation (<xref rid="B70" ref-type="bibr">70</xref>,<xref rid="B71" ref-type="bibr">71</xref>), (iii) epigenetic regulations (like DNA methylations, histone modifications and non-coding RNA regulations) that lead to inter-individual variability in drug responses and adverse reactions, and highlight the implications for personalized medicine (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B72" ref-type="bibr">72</xref>,<xref rid="B73" ref-type="bibr">73</xref>). Furthermore, the effects of HOSPPIs on altering the drug metabolisms varied between healthy and pathological condition, and differed among disease indications (<xref rid="B74" ref-type="bibr">74</xref>). It was therefore essential to collect HOSPPIs to facilitate the prediction of clinical consequence (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
        <p>The HOSPPIs data was identified by literature search using different keyword combinations. For example, when searching for the oligomerization of a DME, ‘‘DME Name’ + oligomer’, ‘‘DME Name’ + oligomerization’, ‘‘DME Name’ + dimer’, ‘‘DME Name’ + trimer’, ‘‘DME Name’ + dimerization’, ‘‘DME Name’ + trimerization’ and ‘‘DME Name’ + protein-protein interaction’ were used; when discovering the transcription factor regulations on a DME, ‘transcription factor + ‘DME Name’’ and ‘transcriptional regulation + ‘DME Name’’ were reviewed; when finding the DNA methylations of a DME, ‘‘DME Name’ + methylation’, ‘‘DME Name’ + epigenetics’ and ‘‘DME Name’ + methylate’ were searched. Moreover, the additional DNA methylation data for all DMEs in INTEDE were further collected using the following processes. First, 1377 series records of a very popular microarray platform (Illumina HumanMethylation450 BeadChip) were collected from the Gene Expression Omnibus (<xref rid="B53" ref-type="bibr">53</xref>), and 136 series records with both patients and healthy individuals data were selected, which contained 16 256 samples of 86 disease indications. Second, all these collected records were sequentially processed by quality control, normalization and batch effect correction (<xref rid="B75" ref-type="bibr">75–78</xref>), and differential methylations were discovered by calculating both <italic>P</italic>-values and <italic>delta-beta</italic> values (<xref rid="B79" ref-type="bibr">79</xref>,<xref rid="B80" ref-type="bibr">80</xref>). According to the definition in previous reports, the threshold of <italic>P</italic>-values was set to 0.05 (<italic>P</italic>-value &lt; 0.05 was considered to be statistically significant (<xref rid="B79" ref-type="bibr">79</xref>)), and the cutoff of <italic>delta-beta</italic> values was set to 0.2 and 0.3 (the absolute value of <italic>delta-beta</italic> &gt;0.3 was considered as ‘significant methylation’ (<xref rid="B79" ref-type="bibr">79</xref>), and 0.3 ≥ |<italic>delta-beta</italic>| &gt;0.2 was reported as ‘moderate methylation’ (<xref rid="B80" ref-type="bibr">80</xref>)). Third, the above differential methylations were discovered among four different sample groups, which included: (i) DME methylation in the normal tissue adjacent to the disease tissue of patients (<italic>blue</italic>), (ii) DME methylation in the disease tissue of patients (<italic>red</italic>), (iii) DME methylation in the normal tissue of healthy individual (<italic>green</italic>) and (iv) DME methylation in the tissue other than the disease tissue of patients (<italic>yellow</italic>). Fourth, the methylation plot across samples was drawn using <italic>ggplot2</italic> in <italic>R</italic> environment, and the violin plots of methylation variation between two studied groups was generated using <italic>ggplot2</italic> and <italic>ggbeeswarm</italic> in <italic>R</italic>. All plots can be viewed online (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S3</xref>) and downloaded from the website.</p>
        <p>Consequently, the HOSPPI information included the interaction types (oligomerization, transcription factor regulation, DNA methylation and drug co-metabolism), the studied diseases (95 diseases standardized in a latest version of International Classification of Diseases (<xref rid="B81" ref-type="bibr">81</xref>), ICD-11), the targeted cell lines (289 cell lines, such as A549, Caco-2, HEK293, HepG2 and MCF-7), the levels of DNA methylation (significant or moderate) together with the corresponding <italic>P</italic>-value and <italic>delta-beta</italic> value, the drugs which metabolism was affected by studied HOSPPIs, the detailed mechanism of a HOSPPI on drug metabolism, and the violin/bar plots illustrating the differential methylation between different sample groups. All in all, INTEDE contained 7849 HOSPPIs between 565 host proteins and 566 DMEs: oligomerization (homo-/hetero-), transcription factor regulation (activation/repression), DNA methylation (hypo-/hyper-), drug co-metabolism (direct/indirect). HOSPPIs data can be assessed in INTEDE (Figure <xref ref-type="fig" rid="F4">4</xref>).</p>
        <fig id="F4" orientation="portrait" position="float">
          <label>Figure 4.</label>
          <caption>
            <p>A typical INTEDE page offering the data of host protein-DME interactions (HOSPPIs). The INTEDE contained 7849 HOSPPIs between 565 host proteins and 566 DMEs. Various types of HOSPPI were in the INTEDE, which included: oligomerization (homo-/hetero-), transcription factor regulation (activation/repression), and DNA methylation (hypo-/hyper-).</p>
          </caption>
          <graphic xlink:href="gkaa755fig4"/>
        </fig>
      </sec>
      <sec id="SEC2-3-3">
        <title>Interactions between xenobiotics and DMEs</title>
        <p>The activity or expression of DMEs could be inhibited or induced by xenobiotics, which, in turn, affected the hepatic clearance of drug and led to the reduced efficacy and therapeutic failure (<xref rid="B82" ref-type="bibr">82–85</xref>). These xenobiotics included: (i) pharmaceutical agents (FDA approved, clinical, preclinical, patented and investigative), (ii) health toxicants (biotoxin, carcinogen, environmental pollutant, mycotoxin, and neurotoxin), (iii) natural substances (biological extract, natural product/mixture and traditional medicine), (iv) agricultural chemicals (fungicides, herbicides and insecticide), (v) additive agents (food additives and cosmetic additives) and (vi) proteins/peptides. Since all these xenobiotics are one of the leading factors of the metabolism-based drug–drug interactions (<xref rid="B5" ref-type="bibr">5</xref>) and the constant inspiration of clinical treatment optimizations (<xref rid="B10" ref-type="bibr">10</xref>), it was essential to collect those xenobiotics-DME interactions (XEOTICs), and clarify the effects of an XEOTIC on modulating the activity or expression of human/microbial DMEs.</p>
        <p>Therefore, the XEOTIC data were systematically searched by literature review in PubMed based on the keyword combinations between ‘DME Name’ and ‘biotoxin’, ‘environmental pollutant’, ‘extract’, ‘fungicides’, ‘inducer’, ‘inhibitor’, ‘insecticides’, ‘nature product’ and ‘pesticides’. Those discovered literatures were evaluated manually to identify the xenobiotics affecting DMEs. The collected data included the name of xenobiotics, the modulation types (inducer and inhibitor), the xenobiotic classifications (additive, agricultural chemical, health toxicant, natural substance, and pharmaceutical agent), the modulation activity (measured by MIC/IC50/Ki values), and the affected cell system (choriocarcinoma, hamster ovary, and high five). All in all, the INTEDE provided 47,778 XEOTICs between 4150 xenobiotics and 501 human or microbial DMEs. These miscellaneous xenobiotics cover all the xenobiotic types described in the previous paragraph (from (i) pharmaceutical agents to (vi) proteins/peptides). All XEOTICs can be assessed in the subpage of INTEDE entitled ‘Xenobiotics-DME Interaction’ (Figure <xref ref-type="fig" rid="F5">5</xref>).</p>
        <fig id="F5" orientation="portrait" position="float">
          <label>Figure 5.</label>
          <caption>
            <p>A typical INTEDE page offering the data of xenobiotics-DME interaction (XEOTIC). The INTEDE provided 47 778 XEOTICs between 4150 xenobiotics and 501 DMEs, which were diverse. Particularly, the types of xenobiotics included (i) pharmaceutical agents (FDA approved, clinical, preclinical and investigative), (ii) health toxicants (biotoxin, carcinogen, environmental pollutant, mycotoxin and neurotoxin), (iii) natural substances (biological extract, natural product and traditional medicine), (iv) agricultural chemicals (fungicides, herbicides and insecticide), (v) additive agents (food additive and cosmetic additive) and (vi) proteins /peptides.</p>
          </caption>
          <graphic xlink:href="gkaa755fig5"/>
        </fig>
      </sec>
    </sec>
    <sec id="SEC2-4">
      <title>Data standardization, access and retrieval</title>
      <p>To make the access and analysis of INTEDE data convenient for all users, the collected raw data were carefully cleaned up and then were systematically standardized, which included the disease standardization, EC classification, unit unification, structure availability and crosslink to various reference databases. Detailed description on the way to clean and standardize data was provided in <xref ref-type="supplementary-material" rid="sup1">Supplementary Method S2</xref>. Furthermore, INTEDE has been smoothly running for months, and tested from different sites around the world. All data could be viewed, accessed, and downloaded (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S4</xref>). Currently, the INTEDE is freely assessed without login requirement by all users at: <ext-link ext-link-type="uri" xlink:href="https://idrblab.org/intede/">https://idrblab.org/intede/</ext-link>.</p>
    </sec>
  </sec>
  <sec id="SEC3">
    <title>INTERACTION CROSSTALK AND PERSPECTIVES</title>
    <p>Although the data of each type of DME interaction in INTEDE were essential for current clinical studies, the crosstalk among different interaction types had emerged to be increasingly important due to the extremely complex mechanisms underlying drug metabolism (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B86" ref-type="bibr">86</xref>,<xref rid="B87" ref-type="bibr">87</xref>). Taking the primary medication for treating <italic>Parkinson's disease</italic>—levodopa—as an example, it must enter the brain and be converted there by the human DME aromatic amino acid decarboxylase (AADC) to its active form—dopamine. However, the delivery of levodopa to blood–brain barrier is greatly restricted by its intestinal metabolisms of both human and gut microbiome (<xref rid="B10" ref-type="bibr">10</xref>). Particularly, the host intestinal AADC and gut microbes <italic>Enterococcus faecalis</italic> and <italic>Eggerthella lenta</italic> can convert levodopa into a different chemical before it reaches the brain, which causes unwanted side effects (<xref rid="B10" ref-type="bibr">10</xref>). Therefore, levodopa should be co-administrated with other drug by collectively considering multiple DME interactions: (i) the MICBIO between the above microbes and brain DME AADC; (ii) the XEOTIC between xenobiotics carbidopa (inhibitor of intestinal AADC) and AADC (<xref rid="B10" ref-type="bibr">10</xref>). In other words, the crosstalk between the MICBIO and XEOTIC of human DME AADC inspired a new strategy that combines AFMT (a microbe inhibitor) and carbidopa (a DME inhibitor) with levodopa, for effectively overcoming the serious side effects of anti-<italic>Parkinson</italic> drug (<xref rid="B10" ref-type="bibr">10</xref>).</p>
    <p>Similarly, the HOSPPI between host protein carboxylesterase and DME CYP3A4 was found as the leading cause of drug resistance, which could therefore be reversed by the XEOTIC between xenobiotics vitamin D and DME CYP3A4 (<xref rid="B87" ref-type="bibr">87</xref>); the HOSPPI between host protein UGT1A1 and microbial DME beta-glucuronidase was reported to cause diarrhea, which needed be relieved by the XEOTIC between xenobiotic amoxapine and the microbial DME beta-glucuronidase (<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B57" ref-type="bibr">57</xref>). Thus, the multiple types of DME interaction in INTEDE might keep inspiring new strategies for dealing with drug resistances and side effects.</p>
    <p>To make the crosstalk analysis of each DME possible, the data of multiple interaction types were systematically collected. As a result, 453 (43.3%) out of 1047 DMEs were described in INTEDE with multiple interaction types. Moreover, the number of interaction data for each type was from thousands to tens of thousands, which made it highly possible to identify the differential features or generalize the common characteristics from these DME-related big data. Meanwhile, because of the lack of multiple interaction types for the remaining 56.7% DMEs, it is essential to continue drug metabolism studies for a further extension of our knowledge on DME interactome.</p>
    <p>In summary, INTEDE is unique in: (i) providing the largest number of DMEs that are manually curated and systematically confirmed based on their metabolizing drug(s), (ii) covering the novel DME data of diverse microbes (parasitizing in different sites of human body) together with their metabolizing drug(s), (iii) describing the comprehensive interactome data from three perspectives for both human and microbial DMEs and (iv) enabling the crosstalk analysis among various types of DME interaction. With the extensive efforts made on describing DME interactome (<xref rid="B3" ref-type="bibr">3–10</xref>) and revealing the crosstalk among interaction types (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B86" ref-type="bibr">86</xref>,<xref rid="B87" ref-type="bibr">87</xref>), those immense, connected and structuralized data provided in INTEDE are expected to have implications for the future practice of clinical treatment optimization (<xref rid="B88" ref-type="bibr">88–92</xref>) and personalized medicine (<xref rid="B93" ref-type="bibr">93–96</xref>).</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sup1">
      <label>gkaa755_Supplemental_File</label>
      <media xlink:href="gkaa755_supplemental_file.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec id="SEC4">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkaa755#supplementary-data">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC5">
    <title>FUNDING</title>
    <p>National Key R&amp;D Program of China [2017YFC0908600, 2018YFC0910500]; National Natural Science Foundation of China [U1909208, 81872798]; Leading Talent of the ‘Ten Thousand Plan’ – National High-Level Talents Special Support Plan, Key R&amp;D Program of Zhejiang Province [2020C03010]; Fundamental Research Funds for the Central Universities [2018QNA7023, 10611CDJXZ238826, 2018CDQYSG0007, CDJZR14468801]; Information Technology Center, Zhejiang University; China Knowledge Centre for Engineering Sciences and Technology [No. CKCEST-2019-1-12]. Funding for open access charge: National Natural Science Foundation of China [81872798].</p>
    <p><italic>Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirchmair</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Goller</surname><given-names>A.H.</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Kunze</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Testa</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>I.D.</given-names></name>, <name name-style="western"><surname>Glen</surname><given-names>R.C.</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>G.</given-names></name></person-group><article-title>Predicting drug metabolism: experiment and/or computation</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2015</year>; <volume>14</volume>:<fpage>387</fpage>–<lpage>404</lpage>.<pub-id pub-id-type="pmid">25907346</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hitchings</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Kelly</surname><given-names>L.</given-names></name></person-group><article-title>Drug metabolism as a community effort</article-title>. <source>Cell Metab.</source><year>2019</year>; <volume>30</volume>:<fpage>235</fpage>–<lpage>237</lpage>.<pub-id pub-id-type="pmid">31390549</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mitchell</surname><given-names>A.L.</given-names></name>, <name name-style="western"><surname>Boland</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Forster</surname><given-names>S.C.</given-names></name>, <name name-style="western"><surname>Gloor</surname><given-names>G.B.</given-names></name>, <name name-style="western"><surname>Tarkowska</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Lawley</surname><given-names>T.D.</given-names></name>, <name name-style="western"><surname>Finn</surname><given-names>R.D.</given-names></name></person-group><article-title>A new genomic blueprint of the human gut microbiota</article-title>. <source>Nature</source>. <year>2019</year>; <volume>568</volume>:<fpage>499</fpage>–<lpage>504</lpage>.<pub-id pub-id-type="pmid">30745586</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>T.A.</given-names></name>, <name name-style="western"><surname>Quintaneiro</surname><given-names>L.M.</given-names></name>, <name name-style="western"><surname>Norvaisas</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Lui</surname><given-names>P.P.</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>M.P.</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>K.Y.</given-names></name>, <name name-style="western"><surname>Herrera-Dominguez</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Sudiwala</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Pessia</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Clayton</surname><given-names>P.T.</given-names></name><etal>et al</etal>.</person-group><article-title>Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans</article-title>. <source>Cell</source>. <year>2017</year>; <volume>169</volume>:<fpage>442</fpage>–<lpage>456</lpage>.<pub-id pub-id-type="pmid">28431245</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Sandhu</surname><given-names>K.V.</given-names></name>, <name name-style="western"><surname>Griffin</surname><given-names>B.T.</given-names></name>, <name name-style="western"><surname>Dinan</surname><given-names>T.G.</given-names></name>, <name name-style="western"><surname>Cryan</surname><given-names>J.F.</given-names></name>, <name name-style="western"><surname>Hyland</surname><given-names>N.P.</given-names></name></person-group><article-title>Gut reactions: breaking down xenobiotic-microbiome interactions</article-title>. <source>Pharmacol. Rev.</source><year>2019</year>; <volume>71</volume>:<fpage>198</fpage>–<lpage>224</lpage>.<pub-id pub-id-type="pmid">30890566</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zimmermann-Kogadeeva</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Wegmann</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>A.L.</given-names></name></person-group><article-title>Mapping human microbiome drug metabolism by gut bacteria and their genes</article-title>. <source>Nature</source>. <year>2019</year>; <volume>570</volume>:<fpage>462</fpage>–<lpage>467</lpage>.<pub-id pub-id-type="pmid">31158845</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>D.G.</given-names></name>, <name name-style="western"><surname>Hulin</surname><given-names>J.U.</given-names></name>, <name name-style="western"><surname>Nair</surname><given-names>P.C.</given-names></name>, <name name-style="western"><surname>Haines</surname><given-names>A.Z.</given-names></name>, <name name-style="western"><surname>McKinnon</surname><given-names>R.A.</given-names></name>, <name name-style="western"><surname>Mackenzie</surname><given-names>P.I.</given-names></name>, <name name-style="western"><surname>Meech</surname><given-names>R.</given-names></name></person-group><article-title>The UGTome: the expanding diversity of UDP glycosyltransferases and its impact on small molecule metabolism</article-title>. <source>Pharmacol. Ther.</source><year>2019</year>; <volume>204</volume>:<fpage>107414</fpage>.<pub-id pub-id-type="pmid">31647974</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>W.</given-names></name></person-group><article-title>Regulation of brain drug metabolizing enzymes and transporters by nuclear receptors</article-title>. <source>Drug Metab. Rev.</source><year>2018</year>; <volume>50</volume>:<fpage>407</fpage>–<lpage>414</lpage>.<pub-id pub-id-type="pmid">30501435</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lauschke</surname><given-names>V.M.</given-names></name>, <name name-style="western"><surname>Barragan</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Ingelman-Sundberg</surname><given-names>M.</given-names></name></person-group><article-title>Pharmacoepigenetics and toxicoepigenetics: novel mechanistic insights and therapeutic opportunities</article-title>. <source>Annu. Rev. Pharmacol. Toxicol.</source><year>2018</year>; <volume>58</volume>:<fpage>161</fpage>–<lpage>185</lpage>.<pub-id pub-id-type="pmid">29029592</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maini Rekdal</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Bess</surname><given-names>E.N.</given-names></name>, <name name-style="western"><surname>Bisanz</surname><given-names>J.E.</given-names></name>, <name name-style="western"><surname>Turnbaugh</surname><given-names>P.J.</given-names></name>, <name name-style="western"><surname>Balskus</surname><given-names>E.P.</given-names></name></person-group><article-title>Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism</article-title>. <source>Science</source>. <year>2019</year>; <volume>364</volume>:<fpage>eaau6323</fpage>.<pub-id pub-id-type="pmid">31196984</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovalchuk</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Q.Y.</given-names></name>, <name name-style="western"><surname>Kelty</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Van Winkle</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name></person-group><article-title>Toxicokinetic interaction between hepatic disposition and pulmonary bioactivation of inhaled naphthalene studied using Cyp2abfgs-null and CYP2A13/2F1-humanized mice with deficient hepatic cytochrome P450 activity</article-title>. <source>Drug Metab. Dispos.</source><year>2019</year>; <volume>47</volume>:<fpage>1469</fpage>–<lpage>1478</lpage>.<pub-id pub-id-type="pmid">31594800</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>P.P.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>G.</given-names></name></person-group><article-title>Pyrrole-protein adducts - a biomarker of pyrrolizidine alkaloid-induced hepatotoxicity</article-title>. <source>J. Food Drug. Anal.</source><year>2018</year>; <volume>26</volume>:<fpage>965</fpage>–<lpage>972</lpage>.<pub-id pub-id-type="pmid">29976414</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkinson</surname><given-names>E.M.</given-names></name>, <name name-style="western"><surname>Ilhan</surname><given-names>Z.E.</given-names></name>, <name name-style="western"><surname>Herbst-Kralovetz</surname><given-names>M.M.</given-names></name></person-group><article-title>Microbiota-drug interactions: impact on metabolism and efficacy of therapeutics</article-title>. <source>Maturitas</source>. <year>2018</year>; <volume>112</volume>:<fpage>53</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">29704918</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doestzada</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Vila</surname><given-names>A.V.</given-names></name>, <name name-style="western"><surname>Zhernakova</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Koonen</surname><given-names>D.P.Y.</given-names></name>, <name name-style="western"><surname>Weersma</surname><given-names>R.K.</given-names></name>, <name name-style="western"><surname>Touw</surname><given-names>D.J.</given-names></name>, <name name-style="western"><surname>Kuipers</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Wijmenga</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacomicrobiomics: a novel route towards personalized medicine</article-title>. <source>Protein Cell</source>. <year>2018</year>; <volume>9</volume>:<fpage>432</fpage>–<lpage>445</lpage>.<pub-id pub-id-type="pmid">29705929</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zimmermann-Kogadeeva</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Wegmann</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>A.L.</given-names></name></person-group><article-title>Separating host and microbiome contributions to drug pharmacokinetics and toxicity</article-title>. <source>Science</source>. <year>2019</year>; <volume>363</volume>:<fpage>eaat9931</fpage>.<pub-id pub-id-type="pmid">30733391</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisenstein</surname><given-names>M.</given-names></name></person-group><article-title>Microbial matters: modelling the complex web of host-microbiome interactions</article-title>. <source>Nature</source>. <year>2020</year>; <volume>581</volume>:<fpage>489</fpage>–<lpage>490</lpage>.<pub-id pub-id-type="pmid">32457524</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>K.N.</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Turnbaugh</surname><given-names>P.J.</given-names></name></person-group><article-title>Precision medicine goes microscopic: engineering the microbiome to improve drug outcomes</article-title>. <source>Cell Host Microbe</source>. <year>2019</year>; <volume>26</volume>:<fpage>22</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">31295421</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cani</surname><given-names>P.D.</given-names></name></person-group><article-title>Human gut microbiome: hopes, threats and promises</article-title>. <source>Gut</source>. <year>2018</year>; <volume>67</volume>:<fpage>1716</fpage>–<lpage>1725</lpage>.<pub-id pub-id-type="pmid">29934437</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savage</surname><given-names>N.</given-names></name></person-group><article-title>The complex relationship between drugs and the microbiome</article-title>. <source>Nature</source>. <year>2020</year>; <volume>577</volume>:<fpage>S10</fpage>–<lpage>S11</lpage>.<pub-id pub-id-type="pmid">31996826</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Patterson</surname><given-names>A.D.</given-names></name></person-group><article-title>The gut microbiome: an orchestrator of xenobiotic metabolism</article-title>. <source>Acta Pharm. Sin. B</source>. <year>2020</year>; <volume>10</volume>:<fpage>19</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">31998605</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geller</surname><given-names>L.T.</given-names></name>, <name name-style="western"><surname>Barzily-Rokni</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Danino</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Jonas</surname><given-names>O.H.</given-names></name>, <name name-style="western"><surname>Shental</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Nejman</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Gavert</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Zwang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>Z.A.</given-names></name>, <name name-style="western"><surname>Shee</surname><given-names>K.</given-names></name><etal>et al</etal>.</person-group><article-title>Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine</article-title>. <source>Science</source>. <year>2017</year>; <volume>357</volume>:<fpage>1156</fpage>–<lpage>1160</lpage>.<pub-id pub-id-type="pmid">28912244</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>D.S.</given-names></name>, <name name-style="western"><surname>Feunang</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>A.C.</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>E.J.</given-names></name>, <name name-style="western"><surname>Marcu</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Sajed</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sayeeda</surname><given-names>Z.</given-names></name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burley</surname><given-names>S.K.</given-names></name>, <name name-style="western"><surname>Berman</surname><given-names>H.M.</given-names></name>, <name name-style="western"><surname>Bhikadiya</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Bi</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Di Costanzo</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Christie</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Dalenberg</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Duarte</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name><etal>et al</etal>.</person-group><article-title>RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D464</fpage>–<lpage>D474</lpage>.<pub-id pub-id-type="pmid">30357411</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbarino</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Whirl-Carrillo</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>R.B.</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>T.E.</given-names></name></person-group><article-title>PharmGKB: a worldwide resource for pharmacogenomic information</article-title>. <source>Wiley Interdiscip. Rev. Syst. Biol. Med.</source><year>2018</year>; <volume>10</volume>:<fpage>e1417</fpage>.<pub-id pub-id-type="pmid">29474005</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uhlen</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Fagerberg</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Hallstrom</surname><given-names>B.M.</given-names></name>, <name name-style="western"><surname>Lindskog</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Oksvold</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Mardinoglu</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Sivertsson</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kampf</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sjostedt</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Asplund</surname><given-names>A.</given-names></name><etal>et al</etal>.</person-group><article-title>Tissue-based map of the human proteome</article-title>. <source>Science</source>. <year>2015</year>; <volume>347</volume>:<fpage>1260419</fpage>.<pub-id pub-id-type="pmid">25613900</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group><article-title>Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D1031</fpage>–<lpage>D1041</lpage>.<pub-id pub-id-type="pmid">31691823</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>UniProt</surname><given-names>C.</given-names></name></person-group><article-title>UniProt: a worldwide hub of protein knowledge</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D506</fpage>–<lpage>D515</lpage>.<pub-id pub-id-type="pmid">30395287</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeske</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Placzek</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Schomburg</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Schomburg</surname><given-names>D.</given-names></name></person-group><article-title>BRENDA in 2019: a european ELIXIR core data resource</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D542</fpage>–<lpage>D549</lpage>.<pub-id pub-id-type="pmid">30395242</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Furumichi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Morishima</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Tanabe</surname><given-names>M.</given-names></name></person-group><article-title>New approach for understanding genome variations in KEGG</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D590</fpage>–<lpage>D595</lpage>.<pub-id pub-id-type="pmid">30321428</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caspi</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Billington</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Keseler</surname><given-names>I.M.</given-names></name>, <name name-style="western"><surname>Kothari</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Krummenacker</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Midford</surname><given-names>P.E.</given-names></name>, <name name-style="western"><surname>Ong</surname><given-names>W.K.</given-names></name>, <name name-style="western"><surname>Paley</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Subhraveti</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Karp</surname><given-names>P.D.</given-names></name></person-group><article-title>The MetaCyc database of metabolic pathways and enzymes - a 2019 update</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D445</fpage>–<lpage>D453</lpage>.<pub-id pub-id-type="pmid">31586394</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jassal</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Matthews</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Viteri</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Lorente</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Fabregat</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Sidiropoulos</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Cook</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Gillespie</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Haw</surname><given-names>R.</given-names></name><etal>et al</etal>.</person-group><article-title>The reactome pathway knowledgebase</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D498</fpage>–<lpage>D503</lpage>.<pub-id pub-id-type="pmid">31691815</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jewison</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Disfany</surname><given-names>F.M.</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Knox</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Maciejewski</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Poelzer</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Huynh</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Arndt</surname><given-names>D.</given-names></name><etal>et al</etal>.</person-group><article-title>SMPDB 2.0: big improvements to the Small Molecule Pathway Database</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>; <volume>42</volume>:<fpage>D478</fpage>–<lpage>D484</lpage>.<pub-id pub-id-type="pmid">24203708</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noronha</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Modamio</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Jarosz</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Guerard</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Sompairac</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Preciat</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Danielsdottir</surname><given-names>A.D.</given-names></name>, <name name-style="western"><surname>Krecke</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Merten</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Haraldsdottir</surname><given-names>H.S.</given-names></name><etal>et al</etal>.</person-group><article-title>The virtual metabolic human database: integrating human and gut microbiome metabolism with nutrition and disease</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D614</fpage>–<lpage>D624</lpage>.<pub-id pub-id-type="pmid">30371894</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>A.P.</given-names></name>, <name name-style="western"><surname>Grondin</surname><given-names>C.J.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>R.J.</given-names></name>, <name name-style="western"><surname>Sciaky</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>McMorran</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Wiegers</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wiegers</surname><given-names>T.C.</given-names></name>, <name name-style="western"><surname>Mattingly</surname><given-names>C.J.</given-names></name></person-group><article-title>The comparative toxicogenomics database: update 2019</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D948</fpage>–<lpage>D954</lpage>.<pub-id pub-id-type="pmid">30247620</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Arndt</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Pon</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Sajed</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>A.C.</given-names></name>, <name name-style="western"><surname>Djoumbou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Knox</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>J.</given-names></name><etal>et al</etal>.</person-group><article-title>T3DB: the toxic exposome database</article-title>. <source>Nucleic Acids Res.</source><year>2015</year>; <volume>43</volume>:<fpage>D928</fpage>–<lpage>D934</lpage>.<pub-id pub-id-type="pmid">25378312</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.F.</given-names></name>, <name name-style="western"><surname>Preissner</surname><given-names>S.C.</given-names></name>, <name name-style="western"><surname>Nickel</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Dunkel</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Preissner</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Preissner</surname><given-names>S.</given-names></name></person-group><article-title>The Transformer database: biotransformation of xenobiotics</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>; <volume>42</volume>:<fpage>D1113</fpage>–<lpage>D1117</lpage>.<pub-id pub-id-type="pmid">24334957</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taskar</surname><given-names>K.S.</given-names></name>, <name name-style="western"><surname>Pilla Reddy</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Burt</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Posada</surname><given-names>M.M.</given-names></name>, <name name-style="western"><surname>Varma</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ullah</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Emami Riedmaier</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Umehara</surname><given-names>K.I.</given-names></name>, <name name-style="western"><surname>Snoeys</surname><given-names>J.</given-names></name><etal>et al</etal>.</person-group><article-title>Physiologically-based pharmacokinetic models for evaluating membrane transporter mediated drug-drug interactions: current capabilities, case studies, future opportunities, and recommendations</article-title>. <source>Clin. Pharmacol. Ther.</source><year>2020</year>; <volume>107</volume>:<fpage>1082</fpage>–<lpage>1115</lpage>.<pub-id pub-id-type="pmid">31628859</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwatsubo</surname><given-names>T.</given-names></name></person-group><article-title>Evaluation of drug-drug interactions in drug metabolism: differences and harmonization in guidance/guidelines</article-title>. <source>Drug Metab. Pharmacokinet.</source><year>2020</year>; <volume>35</volume>:<fpage>71</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">31757749</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tse</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Fain</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Zarin</surname><given-names>D.A.</given-names></name></person-group><article-title>How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider</article-title>. <source>BMJ</source>. <year>2018</year>; <volume>361</volume>:<fpage>k1452</fpage>.<pub-id pub-id-type="pmid">29802130</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.H.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>C.Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.X.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Tu</surname><given-names>G.</given-names></name><etal>et al</etal>.</person-group><article-title>Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1121</fpage>–<lpage>D1127</lpage>.<pub-id pub-id-type="pmid">29140520</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayers</surname><given-names>E.W.</given-names></name>, <name name-style="western"><surname>Beck</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Brister</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Bolton</surname><given-names>E.E.</given-names></name>, <name name-style="western"><surname>Canese</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Comeau</surname><given-names>D.C.</given-names></name>, <name name-style="western"><surname>Funk</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Ketter</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kimchi</surname><given-names>A.</given-names></name><etal>et al</etal>.</person-group><article-title>Database resources of the national center for biotechnology information</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D9</fpage>–<lpage>D16</lpage>.<pub-id pub-id-type="pmid">31602479</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hallen-Adams</surname><given-names>H.E.</given-names></name>, <name name-style="western"><surname>Suhr</surname><given-names>M.J.</given-names></name></person-group><article-title>Fungi in the healthy human gastrointestinal tract</article-title>. <source>Virulence</source>. <year>2017</year>; <volume>8</volume>:<fpage>352</fpage>–<lpage>358</lpage>.<pub-id pub-id-type="pmid">27736307</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwa</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Plottel</surname><given-names>C.S.</given-names></name>, <name name-style="western"><surname>Blaser</surname><given-names>M.J.</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>S.</given-names></name></person-group><article-title>The intestinal microbiome and estrogen receptor-positive female breast cancer</article-title>. <source>J. Natl. Cancer Inst.</source><year>2016</year>; <volume>108</volume>:<fpage>djw029</fpage>.</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nichols</surname><given-names>R.G.</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Patterson</surname><given-names>A.D.</given-names></name></person-group><article-title>Interplay between the host, the human microbiome, and drug metabolism</article-title>. <source>Hum. Genomics</source>. <year>2019</year>; <volume>13</volume>:<fpage>27</fpage>.<pub-id pub-id-type="pmid">31186074</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozkan</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Willcox</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Wemheuer</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Wilcsek</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Coroneo</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>T.</given-names></name></person-group><article-title>Biogeography of the human ocular microbiota</article-title>. <source>Ocul. Surf.</source><year>2019</year>; <volume>17</volume>:<fpage>111</fpage>–<lpage>118</lpage>.<pub-id pub-id-type="pmid">30445178</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>C.</given-names></name></person-group><article-title>Introduction: do microbes in the female reproductive function matter</article-title>. <source>Fertil. Steril.</source><year>2018</year>; <volume>110</volume>:<fpage>325</fpage>–<lpage>326</lpage>.<pub-id pub-id-type="pmid">30037698</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evangelista</surname><given-names>E.A.</given-names></name>, <name name-style="western"><surname>Lemaitre</surname><given-names>R.N.</given-names></name>, <name name-style="western"><surname>Sotoodehnia</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Gharib</surname><given-names>S.A.</given-names></name>, <name name-style="western"><surname>Totah</surname><given-names>R.A.</given-names></name></person-group><article-title>CYP2J2 expression in adult ventricular myocytes protects against reactive oxygen species toxicity</article-title>. <source>Drug Metab. Dispos.</source><year>2018</year>; <volume>46</volume>:<fpage>380</fpage>–<lpage>386</lpage>.<pub-id pub-id-type="pmid">29343610</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stavropoulou</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Pircalabioru</surname><given-names>G.G.</given-names></name>, <name name-style="western"><surname>Bezirtzoglou</surname><given-names>E.</given-names></name></person-group><article-title>The role of cytochromes P450 in infection</article-title>. <source>Front. Immunol.</source><year>2018</year>; <volume>9</volume>:<fpage>89</fpage>.<pub-id pub-id-type="pmid">29445375</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Megaraj</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Sell</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name></person-group><article-title>Suppression of pulmonary CYP2A13 expression by carcinogen-induced lung tumorigenesis in a CYP2A13-humanized mouse model</article-title>. <source>Drug Metab. Dispos.</source><year>2015</year>; <volume>43</volume>:<fpage>698</fpage>–<lpage>702</lpage>.<pub-id pub-id-type="pmid">25710941</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazerska</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Mroz</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Pawlowska</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Augustin</surname><given-names>E.</given-names></name></person-group><article-title>The role of glucuronidation in drug resistance</article-title>. <source>Pharmacol. Ther.</source><year>2016</year>; <volume>159</volume>:<fpage>35</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">26808161</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grayson</surname><given-names>P.C.</given-names></name>, <name name-style="western"><surname>Eddy</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Taroni</surname><given-names>J.N.</given-names></name>, <name name-style="western"><surname>Lightfoot</surname><given-names>Y.L.</given-names></name>, <name name-style="western"><surname>Mariani</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Parikh</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Lindenmeyer</surname><given-names>M.T.</given-names></name>, <name name-style="western"><surname>Ju</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Greene</surname><given-names>C.S.</given-names></name>, <name name-style="western"><surname>Godfrey</surname><given-names>B.</given-names></name><etal>et al</etal>.</person-group><article-title>Metabolic pathways and immunometabolism in rare kidney diseases</article-title>. <source>Ann. Rheum. Dis.</source><year>2018</year>; <volume>77</volume>:<fpage>1226</fpage>–<lpage>1233</lpage>.<pub-id pub-id-type="pmid">29724730</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.H.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.X.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>J.J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.X.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>J.B.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>C.Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F.C.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>W.W.</given-names></name><etal>et al</etal>.</person-group><article-title>Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs</article-title>. <source>Brief. Bioinform.</source><year>2020</year>; <volume>21</volume>:<fpage>649</fpage>–<lpage>662</lpage>.<pub-id pub-id-type="pmid">30689717</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrett</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Wilhite</surname><given-names>S.E.</given-names></name>, <name name-style="western"><surname>Ledoux</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Evangelista</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>I.F.</given-names></name>, <name name-style="western"><surname>Tomashevsky</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Marshall</surname><given-names>K.A.</given-names></name>, <name name-style="western"><surname>Phillippy</surname><given-names>K.H.</given-names></name>, <name name-style="western"><surname>Sherman</surname><given-names>P.M.</given-names></name>, <name name-style="western"><surname>Holko</surname><given-names>M.</given-names></name><etal>et al</etal>.</person-group><article-title>NCBI GEO: archive for functional genomics data sets-update</article-title>. <source>Nucleic Acids Res.</source><year>2013</year>; <volume>41</volume>:<fpage>D991</fpage>–<lpage>D995</lpage>.<pub-id pub-id-type="pmid">23193258</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gautier</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Cope</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Bolstad</surname><given-names>B.M.</given-names></name>, <name name-style="western"><surname>Irizarry</surname><given-names>R.A.</given-names></name></person-group><article-title>Affy-analysis of affymetrix genechip data at the probe level</article-title>. <source>Bioinformatics</source>. <year>2004</year>; <volume>20</volume>:<fpage>307</fpage>–<lpage>315</lpage>.<pub-id pub-id-type="pmid">14960456</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolstad</surname><given-names>B.M.</given-names></name>, <name name-style="western"><surname>Irizarry</surname><given-names>R.A.</given-names></name>, <name name-style="western"><surname>Astrand</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Speed</surname><given-names>T.P.</given-names></name></person-group><article-title>A comparison of normalization methods for high density oligonucleotide array data based on variance and bias</article-title>. <source>Bioinformatics</source>. <year>2003</year>; <volume>19</volume>:<fpage>185</fpage>–<lpage>193</lpage>.<pub-id pub-id-type="pmid">12538238</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Tsutsumi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Midorikawa</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ihara</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S.M.</given-names></name>, <name name-style="western"><surname>Aburatani</surname><given-names>H.</given-names></name></person-group><article-title>Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues</article-title>. <source>Genomics</source>. <year>2005</year>; <volume>86</volume>:<fpage>127</fpage>–<lpage>141</lpage>.<pub-id pub-id-type="pmid">15950434</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>J.L.</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>I.D.</given-names></name>, <name name-style="western"><surname>Teare</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Marchesi</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Nicholson</surname><given-names>J.K.</given-names></name>, <name name-style="western"><surname>Kinross</surname><given-names>J.M.</given-names></name></person-group><article-title>Gut microbiota modulation of chemotherapy efficacy and toxicity</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2017</year>; <volume>14</volume>:<fpage>356</fpage>–<lpage>365</lpage>.<pub-id pub-id-type="pmid">28270698</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ruan</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>P.P.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>G.</given-names></name></person-group><article-title>Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids</article-title>. <source>Arch. Toxicol.</source><year>2019</year>; <volume>93</volume>:<fpage>2197</fpage>–<lpage>2209</lpage>.<pub-id pub-id-type="pmid">31222523</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <label>59.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dieterich</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Schink</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zopf</surname><given-names>Y.</given-names></name></person-group><article-title>Microbiota in the gastrointestinal tract</article-title>. <source>Med. Sci.</source><year>2018</year>; <volume>6</volume>:<fpage>116</fpage>.</mixed-citation>
    </ref>
    <ref id="B60">
      <label>60.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group><article-title>ANPELA: analysis and performance assessment of the label-free quantification workflow for metaproteomic studies</article-title>. <source>Brief. Bioinform.</source><year>2020</year>; <volume>21</volume>:<fpage>621</fpage>–<lpage>636</lpage>.<pub-id pub-id-type="pmid">30649171</pub-id></mixed-citation>
    </ref>
    <ref id="B61">
      <label>61.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klatt</surname><given-names>N.R.</given-names></name>, <name name-style="western"><surname>Cheu</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Birse</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Zevin</surname><given-names>A.S.</given-names></name>, <name name-style="western"><surname>Perner</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Noel-Romas</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Grobler</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Westmacott</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>I.Y.</given-names></name>, <name name-style="western"><surname>Butler</surname><given-names>J.</given-names></name><etal>et al</etal>.</person-group><article-title>Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women</article-title>. <source>Science</source>. <year>2017</year>; <volume>356</volume>:<fpage>938</fpage>–<lpage>945</lpage>.<pub-id pub-id-type="pmid">28572388</pub-id></mixed-citation>
    </ref>
    <ref id="B62">
      <label>62.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Tu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group><article-title>Simultaneous improvement in the precision, accuracy, and robustness of label-free proteome quantification by optimizing data manipulation chains</article-title>. <source>Mol. Cell Proteomics</source>. <year>2019</year>; <volume>18</volume>:<fpage>1683</fpage>–<lpage>1699</lpage>.<pub-id pub-id-type="pmid">31097671</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <label>63.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ballesta</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Innominato</surname><given-names>P.F.</given-names></name>, <name name-style="western"><surname>Dallmann</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Rand</surname><given-names>D.A.</given-names></name>, <name name-style="western"><surname>Levi</surname><given-names>F.A.</given-names></name></person-group><article-title>Systems chronotherapeutics</article-title>. <source>Pharmacol. Re.v</source>. <year>2017</year>; <volume>69</volume>:<fpage>161</fpage>–<lpage>199</lpage>.</mixed-citation>
    </ref>
    <ref id="B64">
      <label>64.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sofi</surname><given-names>H.S.</given-names></name>, <name name-style="western"><surname>Abdal-Hay</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ivanovski</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.S.</given-names></name>, <name name-style="western"><surname>Sheikh</surname><given-names>F.A.</given-names></name></person-group><article-title>Electrospun nanofibers for the delivery of active drugs through nasal, oral and vaginal mucosa: current status and future perspectives</article-title>. <source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><year>2020</year>; <volume>111</volume>:<fpage>110756</fpage>.<pub-id pub-id-type="pmid">32279775</pub-id></mixed-citation>
    </ref>
    <ref id="B65">
      <label>65.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Federhen</surname><given-names>S.</given-names></name></person-group><article-title>Type material in the NCBI taxonomy database</article-title>. <source>Nucleic Acids Res.</source><year>2015</year>; <volume>43</volume>:<fpage>D1086</fpage>–<lpage>D1098</lpage>.<pub-id pub-id-type="pmid">25398905</pub-id></mixed-citation>
    </ref>
    <ref id="B66">
      <label>66.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Bao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Dickman</surname><given-names>K.G.</given-names></name>, <name name-style="western"><surname>Sell</surname><given-names>S.S.</given-names></name>, <name name-style="western"><surname>Mei</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Q.Y.</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name></person-group><article-title>Proximal tubular vacuolization and hypersensitivity to drug-induced nephrotoxicity in male mice with decreased expression of the NADPH-cytochrome P450 reductase</article-title>. <source>Toxicol. Sci.</source><year>2020</year>; <volume>173</volume>:<fpage>362</fpage>–<lpage>372</lpage>.<pub-id pub-id-type="pmid">31693140</pub-id></mixed-citation>
    </ref>
    <ref id="B67">
      <label>67.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.Z.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>L.M.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>M.C.</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>J.K.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>H.D.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>L.S.</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>S.</given-names></name></person-group><article-title>The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants</article-title>. <source>Acta Pharmacol. Sin.</source><year>2017</year>; <volume>38</volume>:<fpage>1184</fpage>–<lpage>1194</lpage>.<pub-id pub-id-type="pmid">28552915</pub-id></mixed-citation>
    </ref>
    <ref id="B68">
      <label>68.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.Q.</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>L.M.</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>Z.Z.</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>Y.S.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>H.Y.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>L.S.</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>S.</given-names></name></person-group><article-title>Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities</article-title>. <source>Sci. Rep.</source><year>2016</year>; <volume>6</volume>:<fpage>23763</fpage>.<pub-id pub-id-type="pmid">27025983</pub-id></mixed-citation>
    </ref>
    <ref id="B69">
      <label>69.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>L.M.</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>Z.Z.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>H.Y.</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>S.N.</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>Y.S.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>L.L.</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>S.</given-names></name></person-group><article-title>Inter-isoform hetero-dimerization of human UDP-glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and impacts on glucuronidation activity</article-title>. <source>Sci. Rep.</source><year>2016</year>; <volume>6</volume>:<fpage>34450</fpage>.<pub-id pub-id-type="pmid">27857056</pub-id></mixed-citation>
    </ref>
    <ref id="B70">
      <label>70.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Bao</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Piekos</surname><given-names>S.C.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>X.B.</given-names></name></person-group><article-title>A transcriptional regulatory network containing nuclear receptors and long noncoding RNAs controls basal and drug-induced expression of cytochrome P450s in HepaRG cells</article-title>. <source>Mol. Pharmacol.</source><year>2018</year>; <volume>94</volume>:<fpage>749</fpage>–<lpage>759</lpage>.<pub-id pub-id-type="pmid">29691280</pub-id></mixed-citation>
    </ref>
    <ref id="B71">
      <label>71.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Ning</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Jeong</surname><given-names>H.</given-names></name></person-group><article-title>Transcriptional regulation of CYP2D6 expression</article-title>. <source>Drug Metab. Dispos.</source><year>2017</year>; <volume>45</volume>:<fpage>42</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">27698228</pub-id></mixed-citation>
    </ref>
    <ref id="B72">
      <label>72.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>X.</given-names></name></person-group><article-title>Epigenetic regulation of drug metabolism and transport</article-title>. <source>Acta Pharm. Sin. B</source>. <year>2015</year>; <volume>5</volume>:<fpage>106</fpage>–<lpage>112</lpage>.<pub-id pub-id-type="pmid">26579435</pub-id></mixed-citation>
    </ref>
    <ref id="B73">
      <label>73.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisel</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Schaeffeler</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Schwab</surname><given-names>M.</given-names></name></person-group><article-title>DNA methylation of ADME genes</article-title>. <source>Clin. Pharmacol. Ther.</source><year>2016</year>; <volume>99</volume>:<fpage>512</fpage>–<lpage>527</lpage>.<pub-id pub-id-type="pmid">27061006</pub-id></mixed-citation>
    </ref>
    <ref id="B74">
      <label>74.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallick</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Taneja</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Moorthy</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Ghose</surname><given-names>R.</given-names></name></person-group><article-title>Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions</article-title>. <source>Expert Opin. Drug Metab. Toxicol.</source><year>2017</year>; <volume>13</volume>:<fpage>605</fpage>–<lpage>616</lpage>.<pub-id pub-id-type="pmid">28537216</pub-id></mixed-citation>
    </ref>
    <ref id="B75">
      <label>75.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>A framework for analyzing DNA methylation data from Illumina Infinium HumanMethylation450 BeadChip</article-title>. <source>BMC Bioinformatics</source>. <year>2018</year>; <volume>19</volume>:<fpage>115</fpage>.<pub-id pub-id-type="pmid">29671397</pub-id></mixed-citation>
    </ref>
    <ref id="B76">
      <label>76.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiao</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Giase</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name></person-group><article-title>Positional effects revealed in Illumina methylation array and the impact on analysis</article-title>. <source>Epigenomics</source>. <year>2018</year>; <volume>10</volume>:<fpage>643</fpage>–<lpage>659</lpage>.<pub-id pub-id-type="pmid">29469594</pub-id></mixed-citation>
    </ref>
    <ref id="B77">
      <label>77.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group><article-title>SSizer: determining the sample sufficiency for comparative biological study</article-title>. <source>J. Mol. Biol.</source><year>2020</year>; <volume>432</volume>:<fpage>3411</fpage>–<lpage>3421</lpage>.<pub-id pub-id-type="pmid">32044343</pub-id></mixed-citation>
    </ref>
    <ref id="B78">
      <label>78.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name><etal>et al</etal>.</person-group><article-title>Discovery of the consistently well-performed analysis chain for SWATH-MS based pharmacoproteomic quantification</article-title>. <source>Front. Pharmacol.</source><year>2018</year>; <volume>9</volume>:<fpage>681</fpage>.<pub-id pub-id-type="pmid">29997509</pub-id></mixed-citation>
    </ref>
    <ref id="B79">
      <label>79.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warden</surname><given-names>C.D.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Tompkins</surname><given-names>J.D.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Riggs</surname><given-names>A.D.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Jove</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>Y.C.</given-names></name></person-group><article-title>COHCAP: an integrative genomic pipeline for single-nucleotide resolution DNA methylation analysis</article-title>. <source>Nucleic Acids Res.</source><year>2013</year>; <volume>41</volume>:<fpage>e117</fpage>.<pub-id pub-id-type="pmid">23598999</pub-id></mixed-citation>
    </ref>
    <ref id="B80">
      <label>80.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>M.A.</given-names></name>, <name name-style="western"><surname>Tiirikainen</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kwee</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Okimoto</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>L.L.</given-names></name></person-group><article-title>Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma</article-title>. <source>PLoS One</source>. <year>2013</year>; <volume>8</volume>:<fpage>e55761</fpage>.<pub-id pub-id-type="pmid">23437062</pub-id></mixed-citation>
    </ref>
    <ref id="B81">
      <label>81.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lancet</surname><given-names>T.</given-names></name></person-group><article-title>ICD-11</article-title>. <source>Lancet</source>. <year>2019</year>; <volume>393</volume>:<fpage>2275</fpage>.<pub-id pub-id-type="pmid">31180012</pub-id></mixed-citation>
    </ref>
    <ref id="B82">
      <label>82.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piekos</surname><given-names>S.C.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Yaqoob</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>H.J.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>X.B.</given-names></name></person-group><article-title>Consequences of phenytoin exposure on hepatic cytochrome P450 expression during postnatal liver maturation in mice</article-title>. <source>Drug Metab. Dispos.</source><year>2018</year>; <volume>46</volume>:<fpage>1241</fpage>–<lpage>1250</lpage>.<pub-id pub-id-type="pmid">29884652</pub-id></mixed-citation>
    </ref>
    <ref id="B83">
      <label>83.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Bao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Q.Y.</given-names></name>, <name name-style="western"><surname>Negishi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name></person-group><article-title>Role of CYP2B in phenobarbital-induced hepatocyte proliferation in mice</article-title>. <source>Drug Metab. Dispos.</source><year>2017</year>; <volume>45</volume>:<fpage>977</fpage>–<lpage>981</lpage>.<pub-id pub-id-type="pmid">28546505</pub-id></mixed-citation>
    </ref>
    <ref id="B84">
      <label>84.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Backman</surname><given-names>J.T.</given-names></name>, <name name-style="western"><surname>Filppula</surname><given-names>A.M.</given-names></name>, <name name-style="western"><surname>Niemi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>P.J.</given-names></name></person-group><article-title>Role of cytochrome P450 2C8 in drug metabolism and interactions</article-title>. <source>Pharmacol. Rev.</source><year>2016</year>; <volume>68</volume>:<fpage>168</fpage>–<lpage>241</lpage>.<pub-id pub-id-type="pmid">26721703</pub-id></mixed-citation>
    </ref>
    <ref id="B85">
      <label>85.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z.J.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>S.</given-names></name></person-group><article-title>Reverse of acute and chronic morphine tolerance by lithocholic acid via down-regulating UGT2B7</article-title>. <source>Front. Pharmacol.</source><year>2016</year>; <volume>7</volume>:<fpage>404</fpage>.<pub-id pub-id-type="pmid">27847477</pub-id></mixed-citation>
    </ref>
    <ref id="B86">
      <label>86.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>A.M.</given-names></name>, <name name-style="western"><surname>Ingelman-Sundberg</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Cherrington</surname><given-names>N.J.</given-names></name>, <name name-style="western"><surname>Aleksunes</surname><given-names>L.M.</given-names></name>, <name name-style="western"><surname>Zanger</surname><given-names>U.M.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Jeong</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Morgan</surname><given-names>E.T.</given-names></name>, <name name-style="western"><surname>Turnbaugh</surname><given-names>P.J.</given-names></name>, <name name-style="western"><surname>Klaassen</surname><given-names>C.D.</given-names></name><etal>et al</etal>.</person-group><article-title>Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21(st) international symposium on microsomes and drug oxidations (MDO)</article-title>. <source>Acta Pharm. Sin. B</source>. <year>2017</year>; <volume>7</volume>:<fpage>241</fpage>–<lpage>248</lpage>.<pub-id pub-id-type="pmid">28388695</pub-id></mixed-citation>
    </ref>
    <ref id="B87">
      <label>87.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>S.Y.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>B.</given-names></name></person-group><article-title>Vitamin D enhances the efficacy of irinotecan through miR-627-mediated inhibition of intratumoral drug metabolism</article-title>. <source>Mol. Cancer Ther.</source><year>2016</year>; <volume>15</volume>:<fpage>2086</fpage>–<lpage>2095</lpage>.<pub-id pub-id-type="pmid">27458137</pub-id></mixed-citation>
    </ref>
    <ref id="B88">
      <label>88.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><etal>et al</etal>.</person-group><article-title>VARIDT 1.0: variability of drug transporter database</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D1042</fpage>–<lpage>D1050</lpage>.<pub-id pub-id-type="pmid">31495872</pub-id></mixed-citation>
    </ref>
    <ref id="B89">
      <label>89.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Tu</surname><given-names>M.J.</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>P.Y.</given-names></name>, <name name-style="western"><surname>Batra</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>A.M.</given-names></name></person-group><article-title>Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression</article-title>. <source>Acta Pharm. Sin. B</source>. <year>2019</year>; <volume>9</volume>:<fpage>639</fpage>–<lpage>647</lpage>.<pub-id pub-id-type="pmid">31193825</pub-id></mixed-citation>
    </ref>
    <ref id="B90">
      <label>90.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Marquez-Lago</surname><given-names>T.T.</given-names></name>, <name name-style="western"><surname>Leier</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Revote</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Jia</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>A.I.</given-names></name>, <name name-style="western"><surname>Webb</surname><given-names>G.I.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><etal>et al</etal>.</person-group><article-title>PRISMOID: a comprehensive 3D structure database for post-translational modifications and mutations with functional impact</article-title>. <source>Brie.f Bioinform.</source><year>2020</year>; <volume>21</volume>:<fpage>1069</fpage>–<lpage>1079</lpage>.</mixed-citation>
    </ref>
    <ref id="B91">
      <label>91.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name></person-group><article-title>NOREVA: enhanced normalization and evaluation of time-course and multi-class metabolomic data</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>W436</fpage>–<lpage>W448</lpage>.<pub-id pub-id-type="pmid">32324219</pub-id></mixed-citation>
    </ref>
    <ref id="B92">
      <label>92.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name></person-group><article-title>What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation</article-title>. <source>ACS Chem. Neurosci.</source><year>2018</year>; <volume>9</volume>:<fpage>1128</fpage>–<lpage>1140</lpage>.<pub-id pub-id-type="pmid">29300091</pub-id></mixed-citation>
    </ref>
    <ref id="B93">
      <label>93.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name></person-group><article-title>NOREVA: normalization and evaluation of MS-based metabolomics data</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>; <volume>45</volume>:<fpage>W162</fpage>–<lpage>W170</lpage>.<pub-id pub-id-type="pmid">28525573</pub-id></mixed-citation>
    </ref>
    <ref id="B94">
      <label>94.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Lou</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group><article-title>Consistent gene signature of schizophrenia identified by a novel feature selection strategy from comprehensive sets of transcriptomic data</article-title>. <source>Brief. Bioinform.</source><year>2020</year>; <volume>21</volume>:<fpage>1058</fpage>–<lpage>1068</lpage>.<pub-id pub-id-type="pmid">31157371</pub-id></mixed-citation>
    </ref>
    <ref id="B95">
      <label>95.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ning</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>A.M.</given-names></name></person-group><article-title>Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics</article-title>. <source>Biochem Pharmacol</source>. <year>2019</year>; <volume>169</volume>:<fpage>113638</fpage>.<pub-id pub-id-type="pmid">31518552</pub-id></mixed-citation>
    </ref>
    <ref id="B96">
      <label>96.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Leier</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Marquez-Lago</surname><given-names>T.T.</given-names></name>, <name name-style="western"><surname>Akutsu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Webb</surname><given-names>G.I.</given-names></name>, <name name-style="western"><surname>Chou</surname><given-names>K.C.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>Computational analysis and prediction of lysine malonylation sites by exploiting informative features in an integrative machine-learning framework</article-title>. <source>Brief. Bioinform.</source><year>2019</year>; <volume>20</volume>:<fpage>2185</fpage>–<lpage>2199</lpage>.<pub-id pub-id-type="pmid">30351377</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
